Dr. Harbeck on the Background of the WSG ADAPT-TP Trial in HR+, HER2+ Breast Cancer


Nadia Harbeck, MD, PhD, discusses the background of the phase 2 WSG ADAPT-TP trial in hormone receptor-positive, HER2-positive early-stage breast cancer.

Nadia Harbeck, MD, PhD, head, Breast Center, chair, Conservative Oncology, Department of Obstetrics and Gynaecology, University of Munich, discusses the background of the phase 2 WSG ADAPT-TP trial (NCT01779206) in hormone receptor (HR)-positive, HER2-positive early-stage breast cancer. 

Findings from the WSG ADAPT-TP trial were presented during the 2021 ESMO Congress, examining the predictive impact of biomarkers on survival after de-escalated neoadjuvant ado-trastuzumab emtansine (T-DM1; Kadcyla) with or without endocrine therapy vs trastuzumab (Herceptin) plus endocrine therapy in 372 patients with HR-positive, HER2-positive early-stage breast cancer, Harbeck explains.

In previous years, the pathologic complete response (pCR) rate resultsshowed a 41% pCR rate after only 4 cycles of T-DM1, Harbeck says. The pCR rates were similar irrespective of whether endocrine therapy was added to TDM-1. Moreover, the control arm reported a 15% pCR rate with trastuzumab plus endocrine therapy, Harbeck concludes.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine